



Revance to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

November 24, 2020

NEWARK, Calif.--(BUSINESS WIRE)--Nov. 24, 2020-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company's President and Chief Executive Officer, Mark Foley, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference.

The fireside chat will be available online beginning December 1 in the investor relations section of the company's website at www.revance.com. The virtual conference will be held from December 1-3, 2020.

About Revance Therapeutics, Inc.

Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval in 2020. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow's feet, as well as in two therapeutic indications - cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance has built a unique portfolio of premium products and services for U.S. aesthetics practices, including the RHA® Collection of dermal fillers in the U.S., the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which includes integrated smart payment, subscription and loyalty digital services. Revance has also partnered with Viatrix (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at www.revance.com.

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

RHA resilient hyaluronic acid® and RHA® are trademarks of TEOXANE SA.

BOTOX® is a registered trademark of Allergan, Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20201124005863/en/): <https://www.businesswire.com/news/home/20201124005863/en/>

Investors

Revance Therapeutics, Inc.:
Jeanie Herbert, 714-325-3584
jherbert@revance.com

or

Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620
laurence@gilmartinir.com

Media

Revance Therapeutics, Inc.:
Sara Fahy, 949-887-4476
sfahy@revance.com

or

General Media:

Y&R:

Jenifer Slaw, 347-971-0906
jenifer.slaw@YR.com

or

Trade Media:

Nadine Tosk, 504-453-8344
nadinepr@gmail.com

Source: Revance Therapeutics, Inc.